Welcome to our dedicated page for CASTLE BIOSCIENCES SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CASTLE BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CASTLE BIOSCIENCES's regulatory disclosures and financial reporting.
Castle Biosciences CEO Derek J. Maetzold reported open-market sales of 19,300 shares of Common Stock of CASTLE BIOSCIENCES INC. He sold 18,650 shares at a weighted-average price of $25.93 on March 17, 2026 and 650 shares at $25.39 on March 18, 2026, leaving 21,479 shares held directly.
The filing notes these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Maetzold also reports indirect ownership of additional Common Stock through multiple family and grantor retained annuity trusts, including 51,566 shares held by The Maetzold Descendants 2020 Trust and other trusts where he serves as trustee or beneficiary.
Castle Biosciences Inc. President and CEO Derek J. Maetzold reported open-market sales of a total of 30,779 shares of common stock on March 13 and 16, 2026, at weighted-average prices of $25.447, $25.964 and $26.680 per share. These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following the sales, he holds 40,779 shares directly and also has indirect holdings through several family and grantor retained annuity trusts.
CASTLE BIOSCIENCES INC Chief Commercial Officer Juvenal Tobin reported an open-market sale of 20,863 shares of common stock. The shares were sold at a weighted-average price of $25.24 per share, with individual trade prices ranging from $24.90 to $25.70. After this transaction, Tobin directly holds 86,825 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the timing was set in advance rather than decided opportunistically.
Castle Biosciences President and CEO Derek J. Maetzold reported a pre-planned combination of option exercise and share sales. On March 11, 2026, he exercised a fully vested stock option for 6,226 shares of common stock at $2.39 per share and received the underlying shares.
That same day, Maetzold and several family-related trusts sold multiple blocks of common stock in open-market transactions at a weighted-average price of about $26.11. On March 12, 2026, he sold an additional 23,179 shares at an average price of $25.279 per share. All sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025. After these trades, he holds 71,558 shares directly, plus additional indirect holdings through various trusts.
CSTL filed a Form 144 reporting proposed sales of Common Stock. The notice lists 20,863 shares with an aggregate market value of $528,251.16 and records a prior sale of 13,200 shares on 12/11/2025 by Tobin Juvenal. The filing identifies recent grants of restricted and performance stock units dated 03/03/2026 and 03/04/2026.
CSTL filing: Notice of proposed sales of Common Stock by reporting person Derek Maetzold
The filing lists multiple dispositions of Common stock by Derek Maetzold under a Form 144 notice, describing sales executed on various dates and securities acquired by gift and compensation (RSUs, PSUs, options). Several transactions in late 2025 and early 2026 are itemized with share counts and proceeds.
Castle Biosciences Chief Financial Officer Frank Stokes sold 6,001 shares of common stock on March 5, 2026 in an open-market transaction at a weighted-average price of $27.98 per share. The sale was made under a prearranged Rule 10b5-1 trading plan adopted on November 13, 2025.
The transaction was executed in multiple trades at prices ranging from $27.51 to $28.41 per share, with the reported price reflecting the weighted average. After this planned sale, Stokes continues to directly own 60,085 shares of Castle Biosciences common stock.
Castle Biosciences director Cole G Bradley reported option exercises and stock sales. On March 5, 2026, Bradley exercised stock options for 4,748 shares and received an equal number of common shares. He then sold a total of 7,403 common shares in open-market transactions and held 19,309 shares directly afterward.
Castle Biosciences Chief Commercial Officer Juvenal Tobin W reported several equity compensation transactions in early March 2026. On March 3, he received a grant of 48,367 Restricted Stock Units (RSUs), each representing one share of common stock, which will vest in four equal annual installments beginning March 3, 2027.
On March 4, previously granted RSUs were exercised into common stock, and 10,399 shares and 3,716 shares of common stock were withheld to cover tax obligations in connection with vested performance or restricted stock units. After these transactions, his directly held common stock and RSU positions increased overall.
Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported several equity compensation transactions involving restricted stock units (RSUs) and common stock. On March 3, 2026, she received a grant of 48,367 RSUs, which vest in four equal annual installments beginning on March 3, 2027.
On March 4, 2026, she exercised or converted RSUs covering 13,811 and 11,960 RSUs at a price of $0.00 per unit, resulting in 25,771 shares of common stock acquired through derivative exercises. The filing also reports dispositions of 6,792 and 2,427 shares of common stock at $28.17 and $27.57 per share, respectively, to satisfy tax withholding obligations in connection with vested performance stock units.
Following these transactions, she holds common stock directly and also has an indirect holding of 97,251 shares of common stock through The Fritz Shorter Trust, of which she and her spouse are trustees and beneficiaries. Each RSU represents the right to receive one share of Castle Biosciences common stock.